On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina  Poder Ejecutivo Nacional, the regulatory agency of Argentina, to initiate the Company’s Phase 2 clinical trial of OT-101, a TGF-antisense, for the treatment of patients with mild to severe COVID-19 infection.

A the time, Argentina had the fifth highest tally of confirmed coronavirus cases worldwide.